Cargando…
Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled
Autores principales: | Verma, Subodh, Dhingra, Nitish K., Bonaca, Marc P., Butler, Javed, Anker, Stefan D., Ferreira, João Pedro, Filippatos, Gerasimos, Januzzi, James L., Lam, Carolyn S.P., Sattar, Naveed, Iwata, Tomoko, Nordaby, Matias, Brueckmann, Martina, Pocock, Stuart J., Packer, Milton |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281175/ https://www.ncbi.nlm.nih.gov/pubmed/37199158 http://dx.doi.org/10.1161/ATVBAHA.123.319156 |
Ejemplares similares
-
Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled
por: Ferreira, João Pedro, et al.
Publicado: (2022) -
Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR‐Reduced trial
por: Packer, Milton, et al.
Publicado: (2021) -
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme
por: Zannad, Faiez, et al.
Publicado: (2022) -
Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial
por: Pocock, Stuart J, et al.
Publicado: (2021) -
Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR‐Reduced
por: Filippatos, Gerasimos, et al.
Publicado: (2022)